Roth Capital Reiterates Buy On Celldex Following Initiation Of Pilot Phase II Study
In a research report released today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Celldex Therapeutics (CLDX) with a $40 price target, following the initiation of a pilot Phase II study to assess safety and efficacy of CDX-301 alone and in combination with Mozobil, in patients undergoing hematopoietic stem cell transplantation (HSCT).
Pantginis wrote, “This Phase II study is supported by both clinical and preclinical data showing the safety and potency of CDX-301 as a mobilizer of HSC. A previous Phase I study in healthy volunteers demonstrated that CDX-301 has a well tolerated safety profile and importantly showed large mobilization of CD34+ HSC into peripheral blood. In preclinical models, CDX-301 successfully achieved immune reconstitution in immune-compromised animal models. With previous data showing feasibility of HSC recruitment from healthy donors, this study should shed light on the efficiency of transplant of recruited HSC in patients with hematological malignancies.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joseph Pantginis has a total average return of -8.7% and a 32.1% success rate. Pantginis has a -14.6% average return when recommending CLDX, and is ranked #3292 out of 3321 analysts.